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 Objective To investigate the use of a translated Chinese version of the pelvic 
pain and urgency/frequency symptom scale as an assessment 
and prognostic tool to evaluate the severity of street-ketamine–
associated lower urinary tract symptoms and their reversibility 
after abstinence.
 Design Cross-sectional study.
 Setting A special designated out-patient clinic in a regional hospital in 
Hong Kong.
 Participants There were 50 patients with street-ketamine–associated lower 
urinary tract symptoms and 20 healthy individuals.
 Main outcome measures Reliability and validity of the questionnaire; frequency 
of individual lower urinary tract symptoms, cystoscopic, 
urodynamic and radiological abnormalities, and their correlation 
with pelvic pain and the urgency/frequency score.
 Results The test-retest reliability coefficient was 0.755 (P<0.001). 
Cronbach’s alpha was 0.974. Mann-Whitney U test proved the 
discriminatory ability of the questionnaire (P<0.001). Patients 
with specific lower urinary tract symptoms had a higher mean 
pelvic pain and urgency/frequency total score compared to those 
without them: frequency (23.8 vs 17.3), nocturia (22.4 vs 14.0), 
urgency (22.5 vs 15.1), dysuria (22.7 vs 13.3), and haematuria (24.8 
vs 16.2). The number of daytime voids and nocturia episodes 
correlated well with pelvic pain and urgency/frequency scores. 
With an increasing score, the likelihood of having cystitis changes, 
urodynamic abnormalities and hydronephrosis increased, while 
the cystometrically determined bladder capacity decreased. 
None of the patients with a score of 16 or below had urodynamic 
abnormality or hydronephrosis. The mean score change in the 
abstinence group was -4.33, versus +3.33 in their counterparts.
 Conclusions The Chinese version of the pelvic pain and urgency/frequency 
questionnaire is reliable and valid for assessment in patients 
with street-ketamine–associated lower urinary tract symptoms. 
The pelvic pain and urgency/frequency score correlates well 
with symptom severity as well as endoscopic, urodynamic and 
radiological abnormalities in patients with street-ketamine–
associated lower urinary tract symptoms. A cut-off total pelvic 
pain and urgency/frequency score of 17 may suggest more serious 
urological sequelae from ketamine abuse. Abstinence from 
ketamine reduced lower urinary tract symptoms, but the extent 
of reversibility of urinary tract damage is yet to be evaluated.
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New knowledge added by this study
• With an increasing pelvic pain and urgency/frequency (PUF) symptom score of above 16 in 
patients with lower urinary tract symptoms after ketamine abuse, the urological sequelae are 
more serious, with increasing likelihood of having cystitis changes, urodynamic abnormalities 
and hydronephrosis, while the cystometrically determined bladder capacity decreases. 
Implications for clinical practice or policy
• The Chinese version of the PUF patient symptom scale can be adopted as an assessment tool 
in patients with lower urinary tract symptoms after ketamine abuse. This tool can be used by 
social workers, teachers, and medical personnel. Those with a score of 17 or above warrant 
more in-depth urological care.
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Introduction
Ketamine is a N-methyl-D-aspartate receptor 
antagonist developed in 1962 as an anaesthetic 
agent.1 It is less potent and shorter-acting than 
phencyclidine and is used as a dissociative 
anaesthetic.2 However, it has been increasingly used 
as a recreational drug by youngsters in clubs and 
parties, including raves. This global phenomenon 
involves countries/regions like China (including 
Hong Kong), Taiwan, Indonesia, Malaysia, Japan, 
Korea, the United Kingdom, Netherlands, Belgium, 
Russia, Canada, and the United States.3,4 A significant 
proportion of street ketamine abusers develop 
lower urinary tract symptoms (LUTS), which have 
 目的 探討使用盆腔疼痛及尿急／頻尿症狀測量表（中文
版）作為氯氨酮濫用者下尿道症狀的一個偵測工具是
否有效。當他們停止濫藥後，這測量表又是否可以作
為一個預後的工具檢測其逆轉情況？
 設計 橫斷面研究。
 安排 香港一所分區醫院的指定特別門診。
 參與者 出現與濫用街頭氯氨酮有關的下尿道症狀的50名病
人，以及20名健康狀況良好的參與者。
 主要結果測量 測量表的信度和效度。出現下尿道症狀的頻率；膀胱
鏡、尿動力學及影像學檢查的異常情況；以及與上述
有關的盆腔疼痛及尿急／頻尿症狀測量表得分。
 結果 重測信度為0.755（P<0.001），Cronbach’s alpha系
數為0.974。曼˙惠特尼U檢定證明測量表具辨別力
（P<0.001）。與健康狀況良好的一組比較，出現下
尿道症狀的氯氨酮濫用者均在以下幾方面有較高的盆
腔疼痛及尿急／頻尿症狀測量表總得分：頻率（23.8
比17.3）、夜尿（22.4比14.0）、尿急（22.5比
15.1）、排尿困難（22.7比13.3）及血尿（24.8比
16.2）。白天排尿和夜尿的次數與測量表得分相關。
測量表得分越高，患者膀胱炎的變化、尿動力學異常
結果及腎積水的可能性便越高，而經膀胱壓力流率測
試的膀胱容量則減少。測量表得分為16分或以下的患
者均沒有尿動力學異常或腎積水的情況。已停止服食
氯氨酮的患者，其測量表得分與之前比較為-4.33。相
比之下，繼續服食氯氨酮的患者，其測量表得分與之
前比較為+3.33。
 結論 盆腔疼痛及尿急／頻尿症狀測量表（中文版）作為偵
測街頭氯氨酮濫用者下尿道症狀的一個工具是可靠
及有效的。測量表得分與濫用者下尿道症狀的嚴重程
度，以及內鏡、尿動力學及影像學異常情況呈正相
關。研究發現測量表總分為17分的截取值可以顯示氯
氨酮濫用者有較為嚴重的泌尿後遺症。停止服食氯氨
酮可以減少下尿道症狀；至於是否可以逆轉氯氨酮對
尿道的傷害，則有待進一步評估。
盆腔疼痛及尿急／頻尿症狀測量表（中文版） 
作為偵測街頭氯氨酮濫用者下尿道症狀的 
一個有效工具
been reported in many different countries.5-14 This 
new clinical entity, first termed ketamine-associated 
ulcerative cystitis,5 or ‘street-ketamine’ associated 
bladder dysfunction,6 is characterised by symptoms 
of lower urinary tract irritation related to ketamine 
use among young adults.7-9 With more studies of this 
entity, it is now known that not only the bladder is 
involved, since it actually comprises a spectrum 
of urinary tract damage ranging from mild cystitis 
changes on endoscopy10 to obstructive uropathy 
and kidney injury.11 This condition is considered to 
be a classical LUTS syndrome (frequency, urgency, 
nocturia, dysuria and/or haematuria) with cystitis and 
contracted bladder that is associated with ketamine 
abuse, which ensues without other known causes 
(bacterial infection, stone disease, or neurogenic 
problem). Cystoscopic or pathological evidence 
of cystitis is not a prerequisite for diagnosing this 
syndrome.
 The pathophysiology of this syndrome is not 
clear. A previous study by our group has examined 
urinary bladder biopsies in these patients, which 
yielded inflammatory changes (polymorph and 
eosinophil infiltration in the urothelium, and 
presence of granulation tissue and congested vessels 
in the lamina propria).15 Under electron microscopy, 
querciphylloid muscle cells with vacuoles at the 
periphery of muscle cells were identified, mimicking 
those in interstitial cystitis.14,15 These bladder biopsy 
features are, therefore, not solely pathognomonic of 
ketamine-associated cystitis.4
 Currently, there is no established diagnostic 
tool to assess LUTS severity in ketamine-induced 
cystitis. In view of its clinical and pathological 
consistency with interstitial cystitis, existing 
symptom scales for assessing interstitial cystitis 
may be adopted for that purpose. There are several 
assessment tools available for interstitial cystitis, 
including the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) criteria,16 the 
University of Wisconsin Symptom Instrument (UWI), 
the O’Leary-Sant instrument (OSI),17 and the pelvic 
pain and urgency/frequency (PUF) patient symptom 
scale.18 Among these, the PUF patient symptom 
scale is a more efficient screening tool for interstitial 
cystitis.19,20 Developed by Parsons et al, the PUF score 
comprises eight questions giving rise to two scores, 
the symptom score and the bother score, with a 
maximum total score of 35.21 It was proven to be an 
accurate method for detecting interstitial cystitis, and 
was validated by intravesical potassium sensitivity 
testing in more than 5000 patients.21 We proposed 
adoption of the PUF score as a useful non-invasive 
diagnostic tool to assess ketamine-induced cystitis 
patients. 
 In this study, we translated and validated the 
Chinese version of the PUF symptom scale (Fig 
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1) and investigated the feasibility of using it as an 
assessment and prognostic tool to evaluate the 
severity of ketamine-associated cystitis. Anticipating 
good correlation between the PUF score and the 
symptomatology, a cut-off value suggestive of more 
serious urological sequelae was also looked for. 
Furthermore, the reversibility of the symptomatology 
of ketamine-associated cystitis after abstinence from 
ketamine was evaluated.
Methods
This study consisted of two components: (1) the 
validation of a Chinese version of PUF symptom scale, 
and (2) the investigation of its use as an assessment 
and prognostic tool in evaluating the severity of 
street-ketamine–associated LUTS as well as symptom 
reversibility after abstinence.
The Chinese version of the pelvic pain and 
urgency/frequency scale
Although health care professionals can use the 
original English version of the PUF scale for assessment 
of patients, we developed the Chinese version with 
a view to popularise the use of the questionnaire 
by local paramedics, domestic researchers, social 
workers, and even ketamine abusers themselves. 
The translation and linguistic validation process was 
similar to that of the Korean version of the PUF scale, 
with evaluated face and content validity.22 It involved 
(1) forward translation by bilingual urologists (two of 
the authors), (2) reconciliation of the two versions 
into one after detailed discussion, (3) back-translation 
of the reconciled Chinese version to English by an 
independent nurse with a bachelor’s degree in 
translation, (4) debriefing and cognitive debriefing 
1 你在日間上厠所多少次？ 3-6 7-10 11-14 15-19 20+
2 a. 你在夜間上厠所多少次？ 0 1 2 3 4+
b. 若你在夜間起床排尿，這情況
困擾你嗎？
從不 間中 時常 經常
3 a. 你現在/以往曾否在性行為時或
之後感到痛楚/不適？
從不 間中 時常 經常
b. 你曾否因為痛楚或尿急不適而
避免性行為？
從不 間中 時常 經常
4 你有沒有膀胱或盆腔（陰道、陰
唇、下腹、會陰、睪丸、或陰囊
位置）的痛楚？
從不 間中 時常 經常
5 a. 若你有此痛楚，程度是： 輕微 中度 嚴重
b. 這些痛楚困擾你嗎？ 從不 間中 時常 經常
6 你排尿後還有尿急的感覺嗎？ 從不 間中 時常 經常
7 a. 你有尿急嗎？若有，程度是： 輕微 中度 嚴重
b. 尿急的情況困擾你嗎？ 從不 間中 時常 經常
8 你有恆常的性行為嗎？ 有/沒有
症狀分數 困擾分數0 1 2 3 4
症狀分數	(1, 2a, 3a, 4, 5a, 6, 7a) =
總分（症狀分數＋困擾分數）=
困擾分數	(2b, 3b, 5b, 7b) =
姓	名：
盆腔痛楚及尿急／尿頻
病人症狀尺度
日	期：
FIG 1.  Chinese version of the pelvic pain and urgency/frequency symptom scale
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involving five ketamine-associated cystitis patients 
and five healthy individuals expressing feedback to 
the questions, and (5) formulation of the finalised 
Chinese version of PUF scale (Fig 1). The test-retest 
reliability of the questionnaire was tested on health 
care workers with a negative history of ketamine use. 
The translated Chinese version of the questionnaire 
was filled in by them twice with a 2-week interval 
and the test-retest reliability was analysed. Further 
analysis of results from questionnaires filled in by 
both health care workers and patients with street-
ketamine–associated LUTS attending our institution 
before January 2009 was then carried out. This 
entailed split-half reliability and internal consistency 
by Cronbach’s alpha, which aimed to evaluate 
the construct validity of the questionnaire. The 
discriminatory ability of the questionnaire was then 
evaluated by the Mann-Whitney U test of the scores 
of the healthy individuals and the patients.
Patient assessment
In Princess Margaret Hospital, a special ‘ketamine 
clinic’ was launched dedicated to evaluating street-
ketamine abusers presenting with LUTS from February 
2009 to May 2010. All the patients attended the clinic 
were recruited into the study. Exclusion criteria were 
LUTS before starting ketamine use, other known 
causes of LUTS (bacterial cystitis with positive urine 
culture), use of urological/neurological medications 
like anti-cholinergic or antipsychotic medications, 
and neurological disorders that might result in 
voiding dysfunction and recent instrumentation of 
the urinary tract.
 Data on the duration and amount of ketamine 
abuse, monthly expenditure on ketamine, LUTS 
(in terms of frequency, nocturia, urgency, dysuria, 
and haematuria according to the 2002 International 
Continence Society definition) were prospectively 
collected. Each patient also completed the PUF 
symptom scale questionnaire during every clinic 
visit. Investigations including blood tests (routine 
renal and liver function tests), urine tests (culture 
and toxicology), renal ultrasonography, flexible 
cystoscopy, and video urodynamic study were 
performed. All patients were assessed, counselled, 
and followed up by urologists from the centre.
Data analyses
Mean PUF scores of patients with or without certain 
symptoms were compared. A correlation analysis 
of quantitative parameters and PUF scores was 
performed. Significance was defined at a P value 
of less than 0.05. Mean PUF scores of patients with 
positive investigation results were compared to those 
without such results. Investigation results of patients 
with different PUF total scores were compared and 
analysed to identify the best cut-off value. Correlation 
analysis between bladder capacity and PUF score was 
also performed. Patients with ketamine abstinence on 
follow-up were selected and the change in their PUF 
scores with time was reviewed. All the data analyses 
were performed with the Statistical Package for the 
Social Sciences (Windows version 17.0; SPSS Inc, 
Chicago [IL], US), except the use of MedCalc (version 
11.6.1.0; MedCalc software, Mariakerke, Belgium) for 
identifying the best cut-off PUF score.
Results
Validation of the Chinese version of pelvic pain 
and urgency/frequency scale score
Twenty health care workers with a negative history 
* The items are: Q1, Q2a, Q2b, Q3a, Q3b, Q4
† The items are: Q5a, Q5b, Q6, Q7a, Q7b, Q8
TABLE 1.  (a) Reliability and (b) internal consistency of the pelvic pain and urgency/
frequency questionnaire
(a) Reliability statistics
(b) Item-total statistics
Item Data
Cronbach’s alpha
Part 1
Value 0.936
No. of items 6*
Part 2
Value 0.966
No. of items 6†
Total N of items 12
Correlation between forms 0.949
Spearman-Brown coefficient
Equal length 0.974
Unequal length 0.974
Guttman split-half coefficient 0.972
Scale mean 
if item 
deleted
Scale 
variance if 
item deleted
Corrected 
item-total 
correlation
Squared 
multiple 
correlation
Cronbach’s 
alpha if item 
deleted
Q1 12.3939 154.871 0.849 0.872 0.972
Q2a 11.7576 146.502 0.905 0.899 0.972
Q2b 12.3030 158.030 0.888 0.928 0.971
Q3a 13.0303 170.218 0.680 0.658 0.975
Q3b 12.7879 162.860 0.817 0.871 0.973
Q4 12.5758 161.127 0.897 0.913 0.971
Q5a 12.4545 157.631 0.964 0.959 0.969
Q5b 12.5152 157.945 0.948 0.968 0.969
Q6 12.5455 160.631 0.926 0.936 0.970
Q7a 12.2121 162.047 0.855 0.878 0.972
Q7b 12.3636 158.114 0.929 0.962 0.970
Q8 12.7273 172.267 0.764 0.811 0.974
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of ketamine use and 15 patients with street-ketamine 
associated LUTS filled out the questionnaire. Of the 
former 20 individuals, 18 (9 males and 9 females) 
completed the questionnaire the second time 2 
weeks after the initial assessment. Their mean 
age was 24 (range, 19-31) years. The mean PUF (± 
standard deviation [SD]) total score was 2.1 ± 2.4 
(mean symptom score, 1.6 ± 1.5; mean bother score, 
0.6 ± 2.0). Regarding the patients, eight were male and 
seven were female. Their mean age was 26 (range, 
18-31) years. Their mean PUF (± SD) total score was 
27.4 ± 7.3 (mean symptom score, 18.3 ± 4.7; mean 
bother score, 9.1 ± 2.8).
 The test-retest reliability coefficients for 
symptom score, bother score, and total score were 
0.753, 0.764, and 0.755, respectively (P<0.001 for all 
three). The equal-length Spearman-Brown coefficient 
for split-test reliability was 0.974, while the Guttman 
coefficient was 0.972. The overall Cronbach’s alpha 
was 0.974. The Cronbach’s alpha for any one of the 
questions being deleted are shown in Table 1. The 
Mann-Whitney U test revealed significant differences 
between scores of the 20 health care workers and 
15 street-ketamine abusers (U=1.50, Z= –4.96 for 
symptom score: U=0, Z= –4.92 for bother score: U=0, 
Z= –4.94 for total score; P<0.001 for all three). The 
respective mean (± SD) score differences were 12.3 ± 
0.8, 7.2 ± 0.5, and 19.5 ± 1.2. 
Assessment results
Fifty-four street ketamine abusers attended the clinic 
during the study period. Altogether four patients were 
excluded: two had LUTS before abusing ketamine, 
one had psychiatric illness with active use of anti-
psychotic medications, while the other had a history 
of childhood meningitis without definitive LUTS. As 
a result, 50 patients (20 males and 30 females) with a 
mean age of 24 (range, 14-48) years were eligible and 
included for analysis.
 The mean (± SD) duration of ketamine abuse 
was 4.7 ± 2.8 years. The mean monthly amount spent 
on ketamine abuse was HK$5006 (range, $200-21 000). 
Common presenting LUTS included: urgency (46 
patients, 92%), frequency (42 patients, 84%), nocturia 
(44 patients, 88%), dysuria (43 patients, 86%), and 
haematuria (34 patients, 68%). The mean (± SD) 
presenting PUF total score was 21.4 ± 7.5 and the 
corresponding symptom and bother scores were 
13.6 ± 5.1 and 7.7 ± 3.0, respectively. 
 The PUF score correlated well with the 
presence/absence of each individual LUTS 
component: urgency (mean PUF, 22.5 ± 7.3 vs 15.1 ± 
5.5; P=0.002), frequency (mean PUF, 23.8 ± 7.4 vs 17.3 
± 5.2; P=0.009), nocturia (mean PUF, 22.4 ± 7.5 vs 14.0 
± 1.4, P<0.001), dysuria (mean PUF, 22.7 ± 7.0 vs 13.3 ± 
6.2; P=0.002), and haematuria (mean PUF, 24.8 ± 7.2 vs 
16.2 ± 5.6; P<0.001) [Fig 2]. Quantitatively, the number 
of day-time voids (frequency episodes) was shown 
to correlate with symptom score (R=0.475, P=0.001) 
and total score (R=0.408, P=0.004), while the number 
of nocturia episodes was correlated with all three: 
symptom, bother, and total scores (R=0.651, 0.557, 
and 0.669, respectively; all P<0.001). The correlations 
between PUF total score and the amount of ketamine 
consumption or duration of abuse were not 
statistically significant (R=0.17, P=0.909 and R=0.234, 
P=0.239, respectively).
 Of the 50 participants, 42 (84%) underwent 
flexible cystoscopy, 31 (62%) underwent urodynamic 
study, and 43 (86%) had renal ultrasonography. In 
all, 30/42 (71%) of the patients had cystitis revealed 
by cystoscopy, 10/31 (32%) had detrusor overactivity, 
3/31 (10%) had vesico-ureteric reflux, 10/31 (32%) 
had poor bladder compliance, and 10/43 (23%) had 
hydronephrosis (8 unilateral and 2 bilateral).
 Higher mean PUF total scores were noted in 
patients with positive cystoscopic, urodynamic and 
ultrasonographic investigation results, namely cystitis 
changes on flexible cystoscopy (mean PUF, 24.0 ± 6.4 
vs 18.6 ± 7.4; P=0.024), detrusor overactivity (mean 
PUF, 25.3 ± 4.9 vs 19.4 ± 7.8; P=0.034), vesico-ureteric 
reflux (mean PUF, 30.0 ± 5.6 vs 20.3 ± 7.1, P=0.029), 
poor bladder compliance (mean PUF, 27.2 ± 5.0 vs 
18.6 ± 6.9; P=0.001), and hydronephrosis (mean PUF, 
bilateral 30.0 ± 7.1 vs unilateral 22.5 ± 4.1 vs negative 
20.6 ± 8.0; P=0.018) [Fig 3]. Biochemically, only four 
patients had mildly deranged serum creatinine 
levels (range, 105-118 μmol/L; upper limit normal, 100 
μmol/L).
 With a PUF total score of 14 or above, patients 
started to develop cystitis changes on flexible 
cystoscopy. Changes indicative of cystitis increased 
FIG 2.  Mean pelvic pain and urgency/frequency (PUF) score in relation to specific 
lower urinary tract symptom component
M
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No
Frequency Nocturia Urgency Dysuria Haematuria
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Symptom score Bother score Total score
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with increasing PUF total score. None of the patients 
with PUF total scores of 16 or below had detrusor 
instability, vesico-ureteric reflux, poor bladder 
compliance, or hydronephrosis. With a higher PUF 
total score, the prevalence of detrusor instability, 
vesico-ureteric reflux, poor bladder compliance, 
and hydronephrosis increased. Receiver operating 
characteristics (ROC) curve analysis was performed. 
The area under the ROC curve was 0.723 (95% 
confidence interval, 0.578-0.840; P=0.0017) for using a 
PUF score to detect the presence of any urodynamic 
or radiological upper urinary tract abnormalities. 
Table 2 summarises the sensitivity, specificity, positive 
likelihood ratios, negative likelihood ratios, positive 
predictive values, and negative predictive values 
for assessing urodynamic abnormalities and upper 
urinary tract damage when using different PUF total 
scores as the cut-off.
 A higher PUF score was associated with smaller 
bladder capacity (correlation= –0.497, P=0.001; Fig 4).
 Of the 50 patients, 24 attended one or more 
follow-up and 18 out of these patients had PUF 
scores documented during follow-up. Only those 
who stopped the medications prescribed (by self or 
by doctor) for symptomatic control were included 
in the analysis. Only nine patients were available 
for analysis (three were active ketamine abusers and 
six had quit the habit). The mean (± SD) abstinence 
period was 24 ± 12 months for the six patients who 
had quit ketamine. After stopping medications for 
symptomatic control, the post-treatment mean 
change in PUF total score in the abstinence group 
was -4.33 (range, -16 to +3), and mean change among 
those who were still abusing ketamine was +3.33 
(range, +1 to +5). 
Discussion
Ketamine abuse has been well reported by 
the Narcotics Division of the Hong Kong SAR 
Government. From 2007 to 2010, it was the most 
common type of drug abused by persons aged 
21 years or under and the second most common 
among all ages (next to heroin). Local urologists 
and family physicians were involved in managing 
and treating ketamine abusers presenting with 
* CI denotes confidence interval, +LR positive likelihood ratio, -LR negative likelihood ratio, +PV positive predictive value, and -PV negative predictive value
TABLE 2.  Sensitivity, specificity, positive likelihood ratios, negative likelihood ratios, positive predictive values, and negative predictive values when using 
different pelvic pain and urgency/frequency total score as cut-off in the detection of the presence of urodynamic or radiological upper urinary tract 
abnormalities*
Criterion Sensitivity 95% CI Specificity 95% CI +LR 95% CI -LR 95% CI +PV 95% CI -PV 95% CI
>15 100.00 80.5-100.0 33.33 18.0-51.8 1.50 0.9-2.4 0.00 0.0-0.0 43.6 27.8 - 60.4 100.0 69.2-100.0
>16 100.00 80.5-100.0 42.42 25.5-60.8 1.74 1.2-2.6 0.00 0.0-0.0 47.2 30.4 - 64.5 100.0 75.3-100.0
>17 94.12 71.3-99.9 51.52 33.5-69.2 1.94 1.4-2.8 0.11 0.02-0.8 50.0 31.9 - 68.1 94.4 72.7-99.9
>18 94.12 71.3-99.9 54.55 36.4-71.9 2.07 1.5-2.9 0.11 0.02-0.7 51.6 33.1 - 69.8 94.7 74.0-99.9
>19 82.35 56.6-96.2 60.61 42.1-77.1 2.09 1.5-3.0 0.29 0.10-0.9 51.9 31.9 - 71.3 87.0 66.4-97.2
>20 70.59 44.0-89.7 63.64 45.1-79.6 1.94 1.3-2.9 0.46 0.2-1.1 50.0 29.1 - 70.9 80.8 60.6-93.4
>21 64.71 38.3-85.8 69.70 51.3-84.4 2.14 1.4-3.2 0.51 0.2-1.2 52.4 29.8 - 74.3 79.3 60.3-92.0
>23 58.82 32.9-81.6 69.70 51.3-84.4 1.94 1.2-3.1 0.59 0.3-1.3 50.0 26.6 - 73.4 76.7 57.7-90.1
FIG 3.  Mean pelvic pain and urgency/frequency (PUF) score and investigation results
DI denotes detrusor instability
FIG 4.  Scatter chart of bladder capacity against pelvic pain and urgency/frequency 
(PUF) total score
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urological symptoms. While there had been no 
standardised assessment tool for this clinical entity, 
in 2007 we started using the PUF symptom scale in 
our patients and since then attained our objective, 
namely to obtain clinical information on the severity 
of urological sequelae in abusers. As investigations 
like flexible cystoscopy and urodynamic study are 
invasive and not readily accepted by ketamine 
abusers, a non-invasive diagnostic tool that can 
truly reflect the symptomatology of these patients is 
needed. An ideal scoring system should also predict 
the outcome of invasive investigations and help in 
counselling patients before they consent to those 
investigations. As in the entity of interstitial cystitis, 
Kushner and Moldwin20 revealed that questionnaires 
do not demonstrate sufficient specificity to serve 
as sole diagnostic indicators, but they can be used 
to screen patients with urinary tract symptoms to 
identify those who should be further examined or 
followed up if they had already been diagnosed.
 Different assessment tools for interstitial 
cystitis have been considered. The NIDDK criteria for 
interstitial cystitis were established in 1987. They were 
intended to be used as a guideline for research.14 
The criteria also involved invasive procedures, 
were purposely designed to be restrictive, and 
therefore were not widely applicable.23 While there 
were several other diagnostic tools for interstitial 
cystitis, including the UWI and the OSI,15 Parsons 
et al18 proposed the PUF scale as a non-invasive and 
accurate diagnostic tool in the assessment of patients 
with interstitial cystitis. A PUF score of 15 or higher 
was associated with an 84% chance of a positive with 
the intravesical potassium sensitivity test.24
 Among the Chinese-speaking communities 
including those in mainland China and Taiwan, the 
Chinese version of PUF questionnaire was translated 
for individual use only, and no formal validation 
has been reported in the western literature. We 
therefore translated and validated the questionnaire 
locally, and tested its linguistic and cultural suitability 
in Hong Kong users. The test-retest reliability was 
demonstrated based on 18 pairs of PUF scores 
completed 2 weeks apart by healthy individuals, 
which resulted in a reliability coefficient of 0.755. Bias 
by memory of questionnaire answers was reduced 
by the 2-week interval between filling of the two 
questionnaires. As only healthy subjects were used 
for analysing test-retest reliability, its usefulness 
cannot be taken to reflect the full range of the scores. 
A more appropriate way of testing the test-retest 
reliability would be to do so in patients with street-
ketamine–associated LUTS, which was not achieved 
because of the high default rate of the patients. 
For the construct validity of the questionnaire, the 
split-half reliability and the internal consistency 
were good. The Mann-Whitney U test for the scores 
between healthy individuals and ketamine abusers 
confirmed the good discriminatory ability of the 
questionnaire in patients with different severity of 
LUTS.
 Our results demonstrated that the PUF score 
related well to symptom severity, both qualitatively 
(presence of frequency, nocturia urgency, dysuria, 
and haematuria) and quantitatively (number of 
day-time voids and number of nocturia events). It 
was closely related to investigation outcomes in 
all aspects: endoscopically, urodynamically and 
radiologically, and as a tool for assessing urological 
sequelae in patients with ketamine-induced cystitis. 
The sequence of progressive urodynamic changes 
with increasing PUF scores may provide hints to 
the cause of upper urinary tract damage, as it is 
suggested that the lower urinary tract is primarily 
affected before the upper tracts, which results 
from a small, shrunken bladder with time.7 Further 
studies to determine the actual pathophysiology of 
ketamine-induced cystitis are required. The persons 
performing the cystoscopic, radiological, and 
urodynamic investigations were not blinded to the 
history of ketamine use, LUTS and PUF score, which 
may have caused possible bias.
 The cut-off value of 17 is suggestive of more 
severe disease status. A total PUF score of higher 
than 16 was associated with a significantly higher rate 
of urological sequelae: endoscopically confirmed 
cystitis (83% vs 47%), detrusor instability (48% vs 
0%), vesico-ureteric reflux (14% vs 0%), poor bladder 
compliance (48% vs 0%), and hydronephrosis (37% vs 
0%). This cut-off had a sensitivity of 100%, specificity 
of 42%, positive predictive value of 47%, and negative 
predictive value of 100% in assessing the presence 
of any urodynamic abnormalities and upper tract 
damage in patients with ketamine-induced cystitis. 
This cut-off value may spare patients with lower 
PUF scores from invasive investigations and those 
with higher scores may warrant more thorough 
investigation.
 Our study failed to demonstrate any correlation 
of PUF score and the serum creatinine level as a 
result of prolonged abuse or progression of the 
disease. This was probably due to the small number 
of patients with renal impairment in our group of 
patients. The highest serum creatinine level among 
the recruited patients was 118 μmol/L only. The 
predictability of the PUF score for biochemical renal 
impairment is uncertain.
 The frequency, amount, and monthly spending 
on ketamine did not show any significant correlation 
with PUF scores. This could be due to the difficulty 
in quantifying the actual amount of ketamine being 
consumed. For most of the patients, the frequency 
of ketamine consumption was irregular and the 
amount consumed each time varied. Furthermore, 
many abusers shared ketamine between friends, so 
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the analysis based on monthly spending on ketamine 
may be inaccurate. Besides, the street-ketamine 
powder obtained by abusers varied as to the degree 
of its purity. There is also the possibility of different 
susceptibility to street-ketamine metabolism in 
different abusers.
 Abstinence from ketamine is thought to be 
associated with improved PUF scores but serial 
follow-up of a larger number of patients is needed 
for confirmation. Due to the high default rate in the 
current study, we failed to obtain a large cohort of 
ketamine abusers who abstained. The social and 
psychological complexity of ketamine abusers 
rendered them difficult to follow-up. Only nine 
patients without medical intervention were available 
to evaluate this aspect of the study. Our limited 
results nevertheless showed a different trend for 
mean changes in PUF score in the abstinence group 
(-4.33) and the continuously abusing group (+3.33). 
This suggests reversibility of LUTS with abstinence 
and may motivate abusers to stop further use of 
ketamine. More concrete proof of recovery is 
required to document PUF score improvements 
together with follow-up urodynamic studies on 
patients with ketamine abstinence.
Conclusion
The Chinese version of PUF questionnaire is reliable 
and has good discriminatory ability for assessment in 
patients with street-ketamine–associated LUTS. The 
PUF score correlates well with symptom severity as 
well as endoscopic, urodynamic, and radiological 
abnormalities in patients with ketamine-induced 
cystitis. A cut-off PUF total score of 17 or more may 
suggest more serious urological sequelae from 
ketamine abuse. Abstinence from ketamine appears 
to help reduce urinary tract symptoms, but the 
reversibility of the urinary tract damage is yet to be 
evaluated.
